Merck (MRK) Gains from Sales and Divestitures (2012)

Merck (MRK) posted quarterly Gains from Sales and Divestitures of $756000.0 for Q4 2012.

Merck (MRK) Gains from Sales and Divestitures (2012) Analysis & Trends

Merck has disclosed Gains from Sales and Divestitures across 1 years of filings, most recently posting $756000.0 for Q4 2012.

In Q4 2012, Gains from Sales and Divestitures changed N/A year-over-year to $756000.0; the TTM figure through Dec 2012 stood at $756000.0 (changed N/A YoY), while the FY2012 annual figure was $756000.0, changed N/A from the prior year.
Gains from Sales and Divestitures was little changed at $756000.0 in Q4 2012.
Over the last five years, Gains from Sales and Divestitures for MRK reached as high as $756000.0 in Q4 2012 and fell as low as $756000.0 in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn

Download Data

Date	Value
Dec 31, 2012	756,000.00
Dec 31, 2012	756,000.00